Raymond James analyst Rahul Sarugaser upgraded Fusion Pharmaceuticals to Strong Buy from Outperform with a price target of $15, up from $12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FUSN:
- Fusion Pharmaceuticals initiated with an Outperform at RBC Capital
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- William Blair says buy these stocks for 2024
- Fusion Pharmaceuticals participates in a conference call with William Blair
- Fusion Pharma participates in a conference call hosted by Cantor Fitzgerald